Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Demonstrates Rapid Immunofluorescence Quantitative Analyzers for POC Testing

By LabMedica International staff writers
Posted on 25 Jul 2023

Getein Biotech, Inc. (Nanjing, China) is showcasing its latest innovations at AACC 2023 including its benchtop immunofluorescence and hematology analyzers as well as its handheld POCT analyzers.

At AACC 2023, Getein is demonstrating the Metis 600 integrated system that provides a suitable solution for immunofluorescence and hematology testing to low-volume laboratories. The combination of immunofluorescence and hematology methodologies in a single system allows for more comprehensive test items to be offered. Metis 600 improves laboratory efficiency through the highest level of automation and accelerates turnaround time for high-volume sample testing. Also on display is the MAGICL 6000 chemiluminescence immunoassay analyzer, a compact and innovative system offering an optimal choice for mid to high-workflow laboratories that need a one-step chemiluminescence solution. Highly productive and compact, this instrument enables fully automated operation and provides the fastest testing speed of any device of its size.

In addition, the company is demonstrating the Getein 1160 immunofluorescence quantitative analyzer - a multi-channel POCT analyzer with four incubation channels and one emergency test channel. It also has a constant test environment with 32℃ to ensure more accurate test results, making it ideal for applications in emergency, critical care (ICU, CCU), outpatient, cardiology, inpatient wards, clinical laboratories, etc. Alongside this, the company is demonstrating the Getein 1100 immunofluorescence quantitative analyzer that is used to measure the concentration of biomarkers in human whole blood, serum, plasma, urine, nasal swab, or saliva samples. The results can be used as an aid in clinical diagnostics of laboratory and point-of-care testing. In addition, Getein is showcasing the CM-400 fully automated clinical chemistry analyzer that is intended to quantitatively analyze chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples, offering constant throughput of 400 T/h.

Related Links:
Getein Biotech, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.